"Antigens, CD20" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.
| Descriptor ID |
D018951
|
| MeSH Number(s) |
D23.050.301.264.035.120 D23.050.301.264.051.120 D23.101.100.110.120 D23.101.100.150.120
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antigens, CD20".
- Chemicals and Drugs [D]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, CD [D23.050.301.264.035]
- Antigens, CD20 [D23.050.301.264.035.120]
- Antigens, Differentiation, B-Lymphocyte [D23.050.301.264.051]
- Antigens, CD20 [D23.050.301.264.051.120]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, CD [D23.101.100.110]
- Antigens, CD20 [D23.101.100.110.120]
- Antigens, Differentiation, B-Lymphocyte [D23.101.100.150]
- Antigens, CD20 [D23.101.100.150.120]
Below are MeSH descriptors whose meaning is more specific than "Antigens, CD20".
This graph shows the total number of publications written about "Antigens, CD20" by people in this website by year, and whether "Antigens, CD20" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 2 | 0 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 2 | 2 |
| 2015 | 2 | 0 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 2 | 1 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antigens, CD20" by people in Profiles.
-
Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma. J Clin Oncol. 2025 07 10; 43(20):2285-2295.
-
Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity. Proc Natl Acad Sci U S A. 2023 01 17; 120(3):e2207291120.
-
Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies. Cytotherapy. 2022 08; 24(8):767-773.
-
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020 10; 26(10):1569-1575.
-
What is new in the treatment of Waldenstrom macroglobulinemia? Leukemia. 2019 11; 33(11):2555-2562.
-
Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. Cytotherapy. 2018 03; 20(3):394-406.
-
Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base. Leuk Lymphoma. 2018 06; 59(6):1375-1383.
-
Follicular lymphoma with hyaline-vascular Castleman disease-like follicles and CD20 positive follicular dendritic cells. Pathology. 2017 Aug; 49(5):544-547.
-
CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia. Mol Ther. 2016 09 29; 24(9):1615-26.
-
CD20-negative diffuse large B-cell lymphoma presenting with lactic acidosis. Am J Hematol. 2015 Mar; 90(3):E49-50.